Cargando…
Therapeutic drug monitoring in oncology - What’s out there: A bibliometric evaluation on the topic
Pharmacological therapy is the mainstay of treatment for cancer patients. Despite wide interpatient variability in systemic drug concentrations for numerous antineoplastics, dosing based on body size remains the predominant approach. Therapeutic drug monitoring (TDM) is used for few antineoplastics...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685987/ https://www.ncbi.nlm.nih.gov/pubmed/36439413 http://dx.doi.org/10.3389/fonc.2022.959741 |
_version_ | 1784835639819108352 |
---|---|
author | Stojanova, Jana Carland, Jane E. Murnion, Bridin Seah, Vincent Siderov, Jim Lemaitre, Florian |
author_facet | Stojanova, Jana Carland, Jane E. Murnion, Bridin Seah, Vincent Siderov, Jim Lemaitre, Florian |
author_sort | Stojanova, Jana |
collection | PubMed |
description | Pharmacological therapy is the mainstay of treatment for cancer patients. Despite wide interpatient variability in systemic drug concentrations for numerous antineoplastics, dosing based on body size remains the predominant approach. Therapeutic drug monitoring (TDM) is used for few antineoplastics in specific scenarios. We conducted a rapid bibliometric evaluation of TDM in oncology to capture a snapshot of research in this area over time and explore topics that reflect development in the field. Reports with the composite, indexed term ‘therapeutic drug monitoring’ in the title and abstract were extracted from MEDLINE (inception to August 2021). Reports related to applications in cancer were selected for inclusion and were tagged by study design, antineoplastic drugs and concepts related to TDM. We present a timeline from 1980 to the present indicating the year of first report of antineoplastic agents and key terms. The reports in our sample primarily reflected development and validation of analytical methods with few relating to clinical outcomes to support implementation. Our work emphasises evidence gaps that may contribute to poor uptake of TDM in oncology. |
format | Online Article Text |
id | pubmed-9685987 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96859872022-11-25 Therapeutic drug monitoring in oncology - What’s out there: A bibliometric evaluation on the topic Stojanova, Jana Carland, Jane E. Murnion, Bridin Seah, Vincent Siderov, Jim Lemaitre, Florian Front Oncol Oncology Pharmacological therapy is the mainstay of treatment for cancer patients. Despite wide interpatient variability in systemic drug concentrations for numerous antineoplastics, dosing based on body size remains the predominant approach. Therapeutic drug monitoring (TDM) is used for few antineoplastics in specific scenarios. We conducted a rapid bibliometric evaluation of TDM in oncology to capture a snapshot of research in this area over time and explore topics that reflect development in the field. Reports with the composite, indexed term ‘therapeutic drug monitoring’ in the title and abstract were extracted from MEDLINE (inception to August 2021). Reports related to applications in cancer were selected for inclusion and were tagged by study design, antineoplastic drugs and concepts related to TDM. We present a timeline from 1980 to the present indicating the year of first report of antineoplastic agents and key terms. The reports in our sample primarily reflected development and validation of analytical methods with few relating to clinical outcomes to support implementation. Our work emphasises evidence gaps that may contribute to poor uptake of TDM in oncology. Frontiers Media S.A. 2022-11-10 /pmc/articles/PMC9685987/ /pubmed/36439413 http://dx.doi.org/10.3389/fonc.2022.959741 Text en Copyright © 2022 Stojanova, Carland, Murnion, Seah, Siderov and Lemaitre https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Stojanova, Jana Carland, Jane E. Murnion, Bridin Seah, Vincent Siderov, Jim Lemaitre, Florian Therapeutic drug monitoring in oncology - What’s out there: A bibliometric evaluation on the topic |
title | Therapeutic drug monitoring in oncology - What’s out there: A bibliometric evaluation on the topic |
title_full | Therapeutic drug monitoring in oncology - What’s out there: A bibliometric evaluation on the topic |
title_fullStr | Therapeutic drug monitoring in oncology - What’s out there: A bibliometric evaluation on the topic |
title_full_unstemmed | Therapeutic drug monitoring in oncology - What’s out there: A bibliometric evaluation on the topic |
title_short | Therapeutic drug monitoring in oncology - What’s out there: A bibliometric evaluation on the topic |
title_sort | therapeutic drug monitoring in oncology - what’s out there: a bibliometric evaluation on the topic |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685987/ https://www.ncbi.nlm.nih.gov/pubmed/36439413 http://dx.doi.org/10.3389/fonc.2022.959741 |
work_keys_str_mv | AT stojanovajana therapeuticdrugmonitoringinoncologywhatsoutthereabibliometricevaluationonthetopic AT carlandjanee therapeuticdrugmonitoringinoncologywhatsoutthereabibliometricevaluationonthetopic AT murnionbridin therapeuticdrugmonitoringinoncologywhatsoutthereabibliometricevaluationonthetopic AT seahvincent therapeuticdrugmonitoringinoncologywhatsoutthereabibliometricevaluationonthetopic AT siderovjim therapeuticdrugmonitoringinoncologywhatsoutthereabibliometricevaluationonthetopic AT lemaitreflorian therapeuticdrugmonitoringinoncologywhatsoutthereabibliometricevaluationonthetopic |